but the e moment ththat really y melted hehearts was t this one. whwhen tisha h hannish andnd dominic brbrandenburg g got to h hug each otother last w week for ththe very fifirst time. . thank y you so muchch dominic had donated blood stem cells to tisha in 2019. a life-saving gift while she was battling cancer. how are you feeling these days i am feeling euphoric i am feeling joy and gratitude through every fiber of my body dominic traveling across the globe from germany to meet tisha and her family at their home in texas. thank you so much it was really really beautiful and a
in my mind landing on the moon. we opened up the potential for so much more. reporter: zynteglo is a gene therapy that modifies their own blood stem cells to eliminate the need for transfusions. it s a one time only procedure with an out of this world price tag, $2.8 million. who should pay for the $2.8 million bill? it s my hope that insurers will jump on board. reporter: at this point it s unclear if the barrons insurer would cover the cost and it s not even the most expensive fda gene approved therapy. dr. david rind is with the price watchdog icer. if you use cost effective analysis, you come to a conclusion that 2.8 million is probably just a little bit beyond the top end of the price range for zynteglo. a more fair price would be $2.1 million. this is absolutely a game changer, anne.
Scientists at Weill Cornell Medicine have finally found a way to correlate mutations with observable characteristics in human cells, taking a step towards understanding how diversified mutations in cells may lead to disease.